脆性 X 综合征：治疗方法的研究进展。
Fragile X syndrome: an update on developing treatment modalities.
机构信息
Seaside Therapeutics, 840 Memorial Drive, Cambridge, Masssachusetts 02139, USA.
出版信息
ACS Chem Neurosci. 2011 Aug 17;2(8):402-10. doi: 10.1021/cn200019z. Epub 2011 Mar 22.
Abstract
Intellectual disability (ID; mental retardation) is considered an immutable condition. Current medical practices are aimed at relieving symptoms and not at altering the underlying cognitive deficits. Scientific advancements from the past decade have led to the exciting possibility that ID may now be treatable. Moreover, pharmaceutical therapies targeting the most common form of inherited ID, Fragile X syndrome (FXS), may become the new benchmark for central nervous system (CNS) drug discovery: seeking cures for neurodevelopmental disorders.
摘要
智力残疾（ID；智力迟钝）被认为是一种不可改变的状况。目前的医疗实践旨在缓解症状，而不是改变潜在的认知缺陷。过去十年的科学进步带来了一个令人兴奋的可能性，即 ID 现在可能是可治疗的。此外，针对最常见的遗传性 ID 形式——脆性 X 综合征（FXS）的药物疗法可能成为中枢神经系统（CNS）药物发现的新基准：寻找神经发育障碍的治疗方法。
相似文献
1
Fragile X syndrome: an update on developing treatment modalities.脆性 X 综合征：治疗方法的研究进展。
ACS Chem Neurosci. 2011 Aug 17;2(8):402-10. doi: 10.1021/cn200019z. Epub 2011 Mar 22.
2
Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics.近期代谢型谷氨酸 4 受体配体鉴定的进展及其作为中枢神经系统治疗药物的潜在应用。
ACS Chem Neurosci. 2011 Aug 17;2(8):433-49. doi: 10.1021/cn200043e. Epub 2011 Jun 14.
3
Fragile X syndrome and targeted treatment trials.脆性X综合征与靶向治疗试验。
Results Probl Cell Differ. 2012;54:297-335. doi: 10.1007/978-3-642-21649-7_17.
4
Potential therapeutic interventions for fragile X syndrome.脆性 X 综合征的潜在治疗干预措施。
Trends Mol Med. 2010 Nov;16(11):516-27. doi: 10.1016/j.molmed.2010.08.005. Epub 2010 Sep 21.
5
Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.脆性 X 综合征的治疗策略：失调的 mGluR 信号及其他。
Neuropsychopharmacology. 2012 Jan;37(1):178-95. doi: 10.1038/npp.2011.137. Epub 2011 Jul 27.
6
[From intellectual disability to new treatment modalities of fragile X syndrome].[从智力残疾到脆性X综合征的新治疗模式]
Ugeskr Laeger. 2014 Feb 24;176(9A):V06130350.
7
Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.脆性 X 综合征的亚慢性给药和代谢型谷氨酸和 GABA B 受体联合药物治疗。
J Pharmacol Exp Ther. 2011 Sep;338(3):897-905. doi: 10.1124/jpet.111.183327. Epub 2011 Jun 2.
8
R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome.R-巴氯芬可逆转脆性X综合征小鼠模型中的社交行为缺陷并降低蛋白质合成水平。
Int J Neuropsychopharmacol. 2015 Mar 28;18(9):pyv034. doi: 10.1093/ijnp/pyv034.
9
Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.代谢型谷氨酸受体5拮抗剂MPEP对两种主要的脆性X综合征小鼠模型表型的抑制作用
Neuropharmacology. 2005 Dec;49(7):1053-66. doi: 10.1016/j.neuropharm.2005.06.004. Epub 2005 Jul 27.
10
Mechanism-based approaches to treating fragile X.基于机制的脆性 X 治疗方法。
Pharmacol Ther. 2010 Jul;127(1):78-93. doi: 10.1016/j.pharmthera.2010.02.008. Epub 2010 Mar 18.
引用本文的文献
1
Understanding the Molecular Basis of Fragile X Syndrome Using Differentiated Mesenchymal Stem Cells.利用分化的间充质干细胞理解脆性X综合征的分子基础
Iran J Child Neurol. 2022 Winter;16(1):85-95. doi: 10.22037/ijcn.v15i4.22070. Epub 2022 Jan 1.
2
New Targeted Treatments for Fragile X Syndrome.脆性X综合征的新型靶向治疗方法。
Curr Pediatr Rev. 2019;15(4):251-258. doi: 10.2174/1573396315666190625110748.
3
GABA-B Agonist Baclofen Normalizes Auditory-Evoked Neural Oscillations and Behavioral Deficits in the Knockout Mouse Model of Fragile X Syndrome.GABA-B 受体激动剂巴氯芬使脆性 X 综合征敲除小鼠模型的听觉诱发神经振荡和行为缺陷正常化。
eNeuro. 2017 Mar 1;4(1). doi: 10.1523/ENEURO.0380-16.2017. eCollection 2017 Jan-Feb.
4
Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders.药物重新利用是开发抗神经精神疾病药物的新机遇。
Schizophr Res Treatment. 2016;2016:6378137. doi: 10.1155/2016/6378137. Epub 2016 Mar 17.
5
Inhibition of Group I Metabotropic Glutamate Receptors Reverses Autistic-Like Phenotypes Caused by Deficiency of the Translation Repressor eIF4E Binding Protein 2.抑制I型代谢型谷氨酸受体可逆转因翻译抑制因子eIF4E结合蛋白2缺乏引起的自闭症样表型。
J Neurosci. 2015 Aug 5;35(31):11125-32. doi: 10.1523/JNEUROSCI.4615-14.2015.
6
Epigenetic findings in autism: new perspectives for therapy.自闭症的表观遗传学研究：治疗的新视角。
Int J Environ Res Public Health. 2013 Sep 11;10(9):4261-73. doi: 10.3390/ijerph10094261.
7
Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant.使用代谢型谷氨酸受体5拮抗剂AFQ056/玛伐谷氨酸盐挽救脆性X智力低下蛋白1基因敲除小鼠的树突棘表型。
Psychopharmacology (Berl). 2014 Mar;231(6):1227-35. doi: 10.1007/s00213-012-2947-y. Epub 2012 Dec 21.
8
ACS chemical neuroscience molecule spotlight on STX209 (arbaclofen).ACS 化学生物学分子特写：STX209（阿巴氯芬）。
ACS Chem Neurosci. 2011 Aug 17;2(8):381. doi: 10.1021/cn200061g. Epub 2011 Jul 6.
9
Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012.通过持续优化 MLPCN 探针 ML012 开发新型 M1 拮抗剂支架。
Bioorg Med Chem Lett. 2012 Aug 1;22(15):5035-40. doi: 10.1016/j.bmcl.2012.06.018. Epub 2012 Jun 15.
10
Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012.从持续优化 MLPCN 探针 ML012 中开发出一种更高选择性的 M1 拮抗剂。
Bioorg Med Chem Lett. 2012 Jan 15;22(2):1044-8. doi: 10.1016/j.bmcl.2011.11.110. Epub 2011 Dec 6.
本文引用的文献
1
A PEDIGREE OF MENTAL DEFECT SHOWING SEX-LINKAGE.显示性连锁的智力缺陷系谱
J Neurol Psychiatry. 1943 Jul;6(3-4):154-7. doi: 10.1136/jnnp.6.3-4.154.
2
Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism.神经行为学模型自闭症：神经肽催产素受体缺失小鼠认知灵活性损伤、社会交往缺陷、攻击行为增加和易发性癫痫的药物干预
Biol Psychiatry. 2011 May 1;69(9):875-82. doi: 10.1016/j.biopsych.2010.12.022. Epub 2011 Feb 21.
3
Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome.脆性 X 综合征小鼠模型的认知功能障碍和前额叶突触异常。
Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2587-92. doi: 10.1073/pnas.1013855108. Epub 2011 Jan 24.
4
A mouse model of the fragile X premutation: effects on behavior, dendrite morphology, and regional rates of cerebral protein synthesis.脆性 X 前突变的小鼠模型：对行为、树突形态和大脑蛋白质合成区域率的影响。
Neurobiol Dis. 2011 Apr;42(1):85-98. doi: 10.1016/j.nbd.2011.01.008. Epub 2011 Jan 8.
5
Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.脆性 X 综合征中 FMR1 基因的表观遗传修饰与 mGluR5 拮抗剂 AFQ056 的不同反应相关。
Sci Transl Med. 2011 Jan 5;3(64):64ra1. doi: 10.1126/scitranslmed.3001708.
6
Fragile X mice: reduced long-term potentiation and N-Methyl-D-Aspartate receptor-mediated neurotransmission in dentate gyrus.脆性 X 综合征小鼠：齿状回长时程增强和 N-甲基-D-天冬氨酸受体介导的神经传递减少。
J Neurosci Res. 2011 Feb;89(2):176-82. doi: 10.1002/jnr.22546. Epub 2010 Dec 8.
7
Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome.过度敏感的 mGluR5 和 ERK1/2 导致脆性 X 综合征小鼠模型海马体中蛋白质过度合成。
J Neurosci. 2010 Nov 17;30(46):15616-27. doi: 10.1523/JNEUROSCI.3888-10.2010.
8
Open-label riluzole in fragile X syndrome.脆性 X 综合征的开放性利鲁唑治疗。
Brain Res. 2011 Mar 22;1380:264-70. doi: 10.1016/j.brainres.2010.10.108. Epub 2010 Nov 5.
9
Self-injurious behavior and fragile X syndrome: findings from the national fragile X survey.自伤行为与脆性 X 综合征：来自全国脆性 X 综合征调查的结果。
Am J Intellect Dev Disabil. 2010 Nov;115(6):473-81. doi: 10.1352/1944-7558-115.6.473.
10
Open-label add-on treatment trial of minocycline in fragile X syndrome.开放性标签添加治疗脆性 X 综合征的米诺环素试验。
BMC Neurol. 2010 Oct 11;10:91. doi: 10.1186/1471-2377-10-91.
Zotero 插件